Treating a melanoma-expressing OVA-bearing mouse by i.p. vaccination of recombinant vaccinia virus expressing OVA (rVACV-OVA) to generate CD8+ TRM and CD8+ TCM, or only CD8+ TRM by i.p. vaccination of rVACV-OVA with i.p. injection of FTY720, it was shown that both CD8+ TRM and CD8+ TCM infiltrated in melanoma are sufficient to mediate anti-tumor immunity, and they can synergize with each other (54). The gene discussed is CD8A; the disease is melanoma.